Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caron A Jacobson

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
Expert Review of Hematology|February 23, 2019
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapyUtkarsh H Acharya, Tejaswini Dhawale, Seongseok Yun, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 19, 2024
Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United StatesOlalekan O Oluwole, Markqayne D Ray, Katherine L Rosettie, et al.
Blood Advances|July 8, 2022
Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphomaJessica S Little, Muneerah M Aleissa, Katherine Beluch, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2021
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaJason Westin, Michael B Maris, Caron A Jacobson, et al.
Transplantation and Cellular Therapy|October 27, 2023
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisCaron A Jacobson, Javier Munoz, Fang Sun, et al.
Hemasphere|January 16, 2025
Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemiaChristine E Ryan, Yue Ren, Svitlana Tyekucheva, et al.
Leukemia & Lymphoma|December 30, 2025
Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5John G Gribben, M Lia Palomba, Eve Limbrick-Oldfield, et al.
Annals of Internal Medicine|December 4, 2023
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness AnalysisAmar H Kelkar, Edward R Scheffer Cliff, Caron A Jacobson, et al.
Blood Cancer Journal|November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myelomaKevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
Blood Advances|September 2, 2021
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphomaJennifer L Crombie, Loretta J Nastoupil, Robert Redd, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
Expert Review of Hematology|February 23, 2019
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapyUtkarsh H Acharya, Tejaswini Dhawale, Seongseok Yun, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 19, 2024
Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United StatesOlalekan O Oluwole, Markqayne D Ray, Katherine L Rosettie, et al.
Blood Advances|July 8, 2022
Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphomaJessica S Little, Muneerah M Aleissa, Katherine Beluch, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2021
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaJason Westin, Michael B Maris, Caron A Jacobson, et al.
Transplantation and Cellular Therapy|October 27, 2023
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisCaron A Jacobson, Javier Munoz, Fang Sun, et al.
Hemasphere|January 16, 2025
Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemiaChristine E Ryan, Yue Ren, Svitlana Tyekucheva, et al.
Leukemia & Lymphoma|December 30, 2025
Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5John G Gribben, M Lia Palomba, Eve Limbrick-Oldfield, et al.
Annals of Internal Medicine|December 4, 2023
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness AnalysisAmar H Kelkar, Edward R Scheffer Cliff, Caron A Jacobson, et al.
Blood Cancer Journal|November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myelomaKevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
Blood Advances|September 2, 2021
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphomaJennifer L Crombie, Loretta J Nastoupil, Robert Redd, et al.
Pageof 14